Cargando…
Clinical utility of denosumab for treatment of bone loss in men and women
While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs have side effects, remain in bone for extended periods, and lead to poor adherence to chronic treatment. Denosumab is a humanized...
Autores principales: | Adler, Robert A, Gill, Ranjodh S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131981/ https://www.ncbi.nlm.nih.gov/pubmed/21753866 http://dx.doi.org/10.2147/CIA.S14565 |
Ejemplares similares
-
Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014) -
Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
por: Dhabhar, Boman
Publicado: (2022) -
Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020) -
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
por: Cavalli, Loredana, et al.
Publicado: (2012) -
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)